menu search

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model Company to participate in upcoming Piper Sandler Inaugural Obesity Investor Day on June 28th Company to host webinar detailing Terns’ Obesity Franchise on June 29th at 11:00 a.m. ET FOSTER CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) […] The post Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual... Read More
Posted: Jun 26 2023, 20:05
Author Name: forextv
Views: 081067

Search within

Pages Search Results: